Stock A099430 BIO PLUS CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bio Plus Co., Ltd

Equities

A099430

KR7099430001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 23/06/2024 BST 		5-day change 1st Jan Change
5,050 KRW -0.59% Intraday chart for Bio Plus Co., Ltd -3.26% -26.49%
06-10 Bio Plus Co., Ltd announces an Equity Buyback for KRW 5,000 million worth of its shares. CI
06-10 Bio Plus Co., Ltd authorizes a Buyback Plan. CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 394,997 402,040 392,878
Enterprise Value (EV) 1 356,150 329,858 337,136
P/E ratio 33.6 x 18.8 x 15.9 x
Yield - 1.01% 1.02%
Capitalization / Revenue 10.6 x 7.09 x 6.04 x
EV / Revenue 9.52 x 5.82 x 5.18 x
EV / EBITDA 18.2 x 12.1 x 11 x
EV / FCF -55,800,240 x 352,805,462 x -66,315,779 x
FCF Yield -0% 0% -0%
Price to Book 4.9 x 3.55 x 3.07 x
Nbr of stocks (in thousands) 57,454 57,931 57,187
Reference price 2 6,875 6,940 6,870
Announcement Date 23/03/22 23/03/23 19/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 11,038 17,021 24,367 37,418 56,719 65,043
EBITDA 1 4,486 7,755 13,338 19,524 27,158 30,516
EBIT 1 3,974 6,888 12,327 18,226 25,271 28,026
Operating Margin 36% 40.47% 50.59% 48.71% 44.56% 43.09%
Earnings before Tax (EBT) 1 2,887 6,719 12,134 14,168 27,471 32,740
Net income 1 2,327 5,623 9,703 10,725 21,137 25,581
Net margin 21.08% 33.04% 39.82% 28.66% 37.27% 39.33%
EPS 2 98.75 228.9 188.8 204.6 368.5 433.4
Free Cash Flow - -2,934 8,504 -6,383 935 -5,084
FCF margin - -17.24% 34.9% -17.06% 1.65% -7.82%
FCF Conversion (EBITDA) - - 63.76% - 3.44% -
FCF Conversion (Net income) - - 87.65% - 4.42% -
Dividend per Share - - - - 70.00 70.00
Announcement Date 30/03/20 30/03/20 31/03/21 23/03/22 23/03/23 19/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales 1 11.12 12.02 14.08 14.13 16.49 - 18.96 17.52
EBITDA - - - - - - - -
EBIT 1 4.618 5.607 6.558 6.42 6.686 - 8.738 7.481
Operating Margin 41.53% 46.63% 46.57% 45.45% 40.56% - 46.1% 42.7%
Earnings before Tax (EBT) - 5.724 6.816 6.807 6.269 - - -
Net income 1 3.256 4.507 4.97 5.25 4.534 6.038 7.467 5.494
Net margin 29.29% 37.49% 35.29% 37.17% 27.5% - 39.39% 31.36%
EPS - - - - - 101.0 - -
Dividend per Share - - - - - - - -
Announcement Date 23/03/22 16/05/22 16/08/22 14/11/22 14/02/23 15/05/23 14/08/23 14/11/23
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 10.7 - - - - -
Net Cash position 1 - 2,704 12,090 38,847 72,183 55,742
Leverage (Debt/EBITDA) 0.002383 x - - - - -
Free Cash Flow - -2,934 8,504 -6,383 935 -5,084
ROE (net income / shareholders' equity) - 44.6% 41.9% 19.6% 21.2% 21.7%
ROA (Net income/ Total Assets) - 25.1% 26.1% 18% 13.4% 11%
Assets 1 - 22,387 37,109 59,500 157,230 233,174
Book Value Per Share 2 316.0 715.0 1,143 1,404 1,955 2,235
Cash Flow per Share 2 147.0 114.0 641.0 732.0 317.0 804.0
Capex 1 546 5,913 1,086 15,312 6,530 21,092
Capex / Sales 4.95% 34.74% 4.46% 40.92% 11.51% 32.43%
Announcement Date 30/03/20 30/03/20 31/03/21 23/03/22 23/03/23 19/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
BIO PLUS CO., LTD Stock Bio Plus Co., Ltd
-26.49% 218M
CSL LIMITED Stock CSL Limited
+2.87% 94.22B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.42% 37.76B
BIOGEN INC. Stock Biogen Inc.
-13.75% 32.5B
UCB Stock UCB
+74.46% 27.75B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-11.88% 16.13B
INCYTE CORPORATION Stock Incyte Corporation
+0.49% 14.19B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.95% 11.42B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+190.36% 11.06B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.07% 9.09B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A099430 Stock
  4. Financials Bio Plus Co., Ltd